Boehringer founding sponsor of CKM Health Initiative Boehringer founding sponsor of CKM Health Initiative Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative
Boehringer expands cancer research at Vienna site Boehringer expands cancer research at Vienna site Boehringer Ingelheim expands cancer research at its Vienna site
Henke-Sass Wolf develop needle free device Henke-Sass Wolf develop needle free device Boehringer Ingelheim partners with Henke-Sass, Wolf to develop innovative needle free injection device for pigs
environmental sustainability commitments environmental sustainability commitments On the occasion of the 2021 UN Climate Change Conference (COP26), Boehringer Ingelheim shares an update on its strategic approach to sustainability
FDA Grants Breakthrough Status to Schizophrenia Treatment FDA Grants Breakthrough Status to Schizophrenia Treatment Boehringer Ingelheim and Click Therapeutics receive FDA Breakthrough Device Designation for schizophrenia prescription digital therapeutic
Fast-Track-Designation-NASH Fast-Track-Designation-NASH Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
New biomass power plant Ingelheim New biomass power plant Ingelheim Boehringer Ingelheim produces its own green energy
Submit Your Opportunity Submit Your Opportunity Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
digital_leader_award_2020 digital_leader_award_2020 Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Boehringer Ingelheim did not manufacture Agent Orange Boehringer Ingelheim did not manufacture Agent Orange Boehringer Ingelheim did not produce Agent Orange. The company did also not contribute to its production by supplying precursors or raw materials.
Partnership to further develop pet market in China Partnership to further develop pet market in China Boehringer Ingelheim invests in partnership to further develop the pet market in China, acquires a stake in New Ruipeng Group
Approval for Aservo EquiHaler equine asthma therapy Approval for Aservo EquiHaler equine asthma therapy Boehringer Ingelheim receives approval for Aservo® EquiHaler®, industry first equine asthma therapy
Boehringer Ingelheim Innovation Prize Boehringer Ingelheim Innovation Prize Find out more about how we’re providing valuable resources to life-science innovators to enable new and emerging science
Boehringer expands production site in Greece Boehringer expands production site in Greece Boehringer expands production site in Greece for new medicine
global-top-employer global-top-employer For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
Launch of Frontline flagship store on Tmall Launch of Frontline flagship store on Tmall Boehringer Ingelheim launches Frontline flagship store on Tmall to sell selling full range of pet parasiticides.
Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio
Acquisition Saint-Herblon site and Coophavet brand Acquisition Saint-Herblon site and Coophavet brand Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
Agreement-to-acquire-Labor-Dr.-Merk Agreement-to-acquire-Labor-Dr.-Merk Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
A tool to aid in the prevention of African swine fever A tool to aid in the prevention of African swine fever ASF COMBAT is an online management and biosecurity assessment tool aimed at reducing the African swine fever introduction risk level.
Two new claims for Nexgard range in EU and Australia Two new claims for Nexgard range in EU and Australia Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Trailr2-cdh17-antibody-phase1-trial Trailr2-cdh17-antibody-phase1-trial Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers
Research-collaboration-Gubra-obesity-treatment Research-collaboration-Gubra-obesity-treatment Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
Research ruminant animal health well-being Research ruminant animal health well-being Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research